Dr Raza Alikhan is a consultant haematologist at the Haemophilia and Thrombosis Centre, University Hospital of Wales and member of the British Society for Haematology (BSH) Thrombosis and Haemostasis Task Force and Guideline Committee and Chair of the BSH Cancer Associated Thrombosis Guideline Writing Group. He is a Fellow of the Royal College of Pathologists and a Member of the Royal College of Physicians having received his medical degree from the University of London and completed postgraduate studies in London and Oxford. He defended his doctoral thesis on venous thromboembolism and prophylaxis in medical patients and was the UK National Lead Investigator for the rivaroxaban medical thromboprophylaxis study (MARINER). He is he UK Chief Investigator for both the apixaban treatment of cancer associated thrombosis study (CARAVAGGIO) and the apixaban length of stay pulmonary embolism study (ALPHA-PE).
Dr Alikhan has been involved in phase II–IV anticoagulant clinical trials since the late 90s. His current research interests include the identification of risk factors and outcomes associated with anticoagulation related bleeding. He is the UK Chief Investigator for the andexanet alfa DOAC and LMWH antidote study (ANNEXA-4) and is a member of the steering committee for the oral anticoagulant agent associated bleeding events reporting system (ORANGE) and the secure anonymised information linkage bleeding risk evaluation (SABRE) study. He has authored more than 100 conference abstracts, peer-reviewed papers and book chapters on thrombosis and haemostasis.